Taking the Brakes Off Targeted Protein Degradation

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) cholesterol levels.
• PCSK9 promotes the degradation of the LDL receptor (LDLR) in lysosomes, thereby reducing LDL clearance from the blood.
• Elevated LDL cholesterol is a major risk factor for cardiovascular disease.

Purpose of the Study:

• To identify novel small molecules that can bind to PCSK9.
• To develop a proof-of-concept degrader molecule targeting the PCSK9 protein-protein interaction.
• To explore a new therapeutic strategy for modulating PCSK9 activity.

Main Methods:

• High-throughput screening to identify PCSK9-binding ligands.
• Structure-based drug design to optimize ligand properties.
• Development and validation of a small molecule degrader for PCSK9.

Main Results:

• Identification of novel small molecule ligands for PCSK9.
• Successful conversion of a ligand into a functional PCSK9 degrader.
• Demonstration of a novel approach to modulate PCSK9 function.

Conclusions:

• Novel PCSK9 ligands have been identified.
• A proof-of-concept PCSK9 degrader offers a new strategy for LDL cholesterol management.
• Targeting PCSK9 protein-protein interactions presents a promising therapeutic avenue.